Neurocrine Biosciences Stock Investor Sentiment

NBIX Stock  USD 110.07  0.24  0.22%   
Slightly above 62% of Neurocrine Biosciences' investor base is looking to short. The analysis of the overall investor sentiment regarding Neurocrine Biosciences suggests that many traders are alarmed. Neurocrine Biosciences' investing sentiment can be driven by a variety of factors including economic data, Neurocrine Biosciences' earnings reports, geopolitical events, and overall market trends.
  
a minute ago at finance.yahoo.com         
Neurocrines Phase II schizophrenia trial fails to meet primary endpoint
Yahoo News
a day ago at finance.yahoo.com         
Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGRE...
Yahoo News
2 days ago at thelincolnianonline.com         
Primecap Management Co. CA Sells 10,290 Shares of Neurocrine Biosciences, Inc.
news
few days ago at insidermonkey.com         
Is Neurocrine Biosciences, Inc. a Best Biotech Stock According to Billionaires?
insidermonkey News
few days ago at finance.yahoo.com         
Neurocrine Biosciences Presents New KINECT-HD Data Showing Significant Reduction in Chorea Across Bo...
Yahoo News
few days ago at thelincolnianonline.com         
Neurocrine Biosciences, Inc. Shares Sold by AlphaQuest LLC
news
few days ago at thelincolnianonline.com         
Neurocrine Biosciences, Inc. Shares Sold by Securian Asset Management Inc.
news
six days ago at www.macroaxis.com         
Acquisition by Roberts Eiry of 1860 shares of Neurocrine Biosciences subject to Rule 16b-3
Macroaxis News
over a week ago at finance.yahoo.com         
aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update
Yahoo News
over a week ago at finance.yahoo.com         
Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
Yahoo News
over a week ago at thelincolnianonline.com         
Edgestream Partners L.P. Grows Stock Position in Neurocrine Biosciences, Inc.
news
over a week ago at thelincolnianonline.com         
Brokerages Set Neurocrine Biosciences, Inc. Price Target at 166.90
news
over a week ago at thelincolnianonline.com         
Sound View Wealth Advisors Group LLC Acquires 652 Shares of Neurocrine Biosciences, Inc.
news
over a week ago at thelincolnianonline.com         
Acquisition by Roberts Eiry of 2113 shares of Neurocrine Biosciences subject to Rule 16b-3
news
over a week ago at thelincolnianonline.com         
Andra AP fonden Sells 77,600 Shares of Neurocrine Biosciences, Inc.
news
Far too much social signal, news, headlines, and media speculation about Neurocrine Biosciences that are available to investors today. That information is available publicly through Neurocrine media outlets and privately through word of mouth or via Neurocrine internal channels. However, regardless of the origin, that massive amount of Neurocrine data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Neurocrine Biosciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Neurocrine Biosciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Neurocrine Biosciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Neurocrine Biosciences alpha.

Neurocrine Biosciences Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Additional Tools for Neurocrine Stock Analysis

When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.